Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1255477 | 1.00 | HCRTR1 (0.43) | HCRTR1HCRTR2NAMPTTSPOOPRK1 | |
| SCHEMBL1256734 | 0.98 | HCRTR1 (0.41) | HCRTR1HCRTR2NAMPTTSPOOPRK1 | |
| SCHEMBL5775373 | 0.86 | HCRTR1 (0.38) | HCRTR1HCRTR2NAMPTTSPOOPRK1 | |
| SCHEMBL1257968 | 0.84 | HCRTR1 (0.40) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1256916 | 0.84 | HCRTR1 (0.39) | HCRTR1HCRTR2NAMPTTSPOOPRK1 | |
| SCHEMBL1257813 | 0.84 | HCRTR1 (0.41) | HCRTR1HCRTR2NAMPTTSPOOPRK1 | |
| SCHEMBL1257480 | 0.83 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL1256839 | 0.83 | HCRTR1 (0.42) | HCRTR1HCRTR2NAMPT | |
| SCHEMBL1257477 | 0.83 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL1776678 | 0.81 | HCRTR1 (0.43) | HCRTR1HCRTR2NAMPTTSPOOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928124-B2 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-19 | — | — | US | disclosed |
| US-7928125-B2 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-19 | — | — | US | disclosed |
| US-7897618-B2 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-7893090-B2 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2011-02-22 | — | — | US | disclosed |
| US-20090036442-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. | 2009-02-05 | — | — | US | disclosed |
| US-20090012083-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-20090012122-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-7470710-B2 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-12-30 | — | — | US | disclosed |
| US-20080318944-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. | 2008-12-25 | — | — | US | disclosed |
| EP-1705179-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2006-09-27 | — | — | EP | disclosed |
| US-20040180887-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2004-09-16 | — | — | US | disclosed |
| EP-1399441-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002561-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180887-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885NAMPT 867/4885 |
| US-20090012122-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885NAMPT 531/4885 |
| US-20080318944-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885NAMPT 531/4885 |
| US-20090012083-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885NAMPT 531/4885 |
| US-20090036442-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885NAMPT 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.